We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics


Provides full range of instrumentation, reagent kits, software and quality control systems to clinical laboratories. ... read more Featured Products: More products

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Early Differences in Cytokine Production Distinguish Severity of COVID-19

By LabMedica International staff writers
Posted on 27 Jan 2021
Print article
Image: The Bio-Plex Pro Human Cytokine Screening 48-plex panel (Photo courtesy of Bio-Rad Laboratories).
Image: The Bio-Plex Pro Human Cytokine Screening 48-plex panel (Photo courtesy of Bio-Rad Laboratories).
Most COVID-19 patients experience asymptomatic/mild symptoms, but some suffer critical symptoms requiring intensive care. It is important to determine how asymptomatic/mild patients react to SARS-CoV-2 infection and suppress virus spread.

It has been shown that several components of the immune response are dysregulated in COVID-19 patients with severe symptoms. Monocytes and macrophages were significantly dysregulated in severe patients. Dendritic cells and natural killer (NK) cells were depleted in COVID-19 patients compared to healthy controls, and it has been determined that those cells are dysregulated in the setting of SARS-CoV-2 infection.

A team of Clinical Virologists at the Kobe University Graduate School of Medicine (Kobe, Japan) analyzed cytokines induced by the innate immune response in 95 COVID-19 patients (median age, 50 years; 55% male) with different disease severities during their early phase of infection, less than 10 days after symptom onset or after an asymptomatic patient being notified of contact with a positive case. Of the patients, 16 were asymptomatic, 49 had mild disease, 11 had moderate disease, and 19 had severe disease.

The diagnosis of COVID-19 was determined by the detection of SARS-CoV-2 genome in a nasopharyngeal swab sample by polymerase chain reaction (PCR). Serum samples were subjected to the measurements of cytokines, chemokines, and growth factor (CCG) with the Bio-Plex Pro Human Cytokine Screening 48-plex panel (Bio-Rad Laboratories, Hercules, CA, USA) and the results were read using the Bio-Plex 200 system.

The team reported that IL-12 level was significantly higher in both the asymptomatic group and the mild group compared to the moderate and severe groups. Similarly, serum level of IL-2 was found to be significantly higher in the asymptomatic and mild COVID-19 patients compared with moderate and severe patients. Meanwhile, serum level of IL-18 was significantly higher in the symptomatic COVID-19 patients compared with asymptomatic patients and healthy controls. Similarly, the team found that IL-6 level increased with the severity level of COVID-19 in the acute phase. The investigators noted that IL-2 is also known as a growth factor for NK cells and has a synergistic effect with IL-18 to enhance the cytotoxicity and expansion of NK cells.

The authors concluded that their investigation was the first to show that during the acute phase of infection, significantly higher levels of IL-12 and IL-2 were induced in COVID-19 patients with asymptomatic and mild symptoms compared to those with moderate and severe symptoms, indicating the important roles of these two cytokines in the protection from severe COVID19. The study was published on January 7, 2021 in the Journal of Infectious Diseases.

Related Links:
Kobe University Graduate School of Medicine
Bio-Rad Laboratories

Gold Supplier
ADAMTS13 Activity Assay
HemosIL ACUSTAR ADAMTS13 Activity Assay
Gold Supplier
SARS-CoV2 Antigen Rapid Test
SARS-CoV2 Antigen Rapid Test
COVID-19 Antigen Test
Instant-view PLUS COVID-19 Antigen Test
Silver Supplier
Remote Lab Review Software
CellaVision Remote Review Software

Print article
BIOHIT  Healthcare OY



view channel
Image: Quidel Receives Amended FDA Emergency Use Authorization for New AI-Powered Sofia Q Rapid Antigen Test Device (Photo courtesy of Quidel Corporation)

Quidel Receives Amended FDA Emergency Use Authorization for New AI-Powered Sofia Q Rapid Antigen Test Device

Quidel Corporation (San Diego, CA, USA) has received an amended Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) allowing the company to market Sofia Q, its latest addition... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.